TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pneumococcal Vaccination of Fiji Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infant aged between 6 and 8 weeks~2. No significant maternal or perinatal history~3. Written and signed parental/caregiver consent~4. Lives within 30 minutes of the health clinic~5. Family anticipate living in the study area for the next 2 years~Exclusion Criteria:~1. Known allergy to any component of the vaccine~2. Allergic reaction or anaphylactoid reaction with previous vaccines~3. Known immunodeficiency disorder~4. HIV positive mother (many women are tested for HIV antenatally, however a test is not planned; therefore it would be based on clinic records or self report)~5. Known thrombocytopenia or coagulation disorder~6. On immunosuppressive medication~7. Received any blood product since birth~8. Severe congenital anomaly~9. Chronic or progressive disease~10. Seizure disorder~11. History of invasive Pneumococcal, meningococcal, or Haemophilus influenzae diseases~12. Moderate or severe acute infection (temporary exclusion); Minor illnesses such as an uncomplicated upper respiratory tract infection, localized skin infections, or mild diarrhea will not be an exclusion criterion

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 8 Weeks
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
- B (Type: EXPERIMENTAL): PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
- C (Type: EXPERIMENTAL): PCV at 6 weeks and 14 weeks; PPS at 18 months
- D (Type: EXPERIMENTAL): PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
- E (Type: EXPERIMENTAL): PCV at 14 weeks; PPS at 18 months
- F (Type: EXPERIMENTAL): PCV at 14 weeks; PPS at 12 months and 18 months
- G (Type: EXPERIMENTAL): No PCV; PPS at 12 months and 18 months
- H (Type: ACTIVE_COMPARATOR): No PCV; PPS at 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetics currently receiving a stable dose of TZD monotherapy (pioglitazone 30mg or 45mg, or rosiglitazone 4mg or 8mg) for at least 12 weeks prior to screening.~* Hemoglobin A1c (HbA1c) \> = 7.0% and \< = 10.5%~* Body mass index \< = 45kg/m2~* Fasting C-peptide \> = 1 ng/mL~Exclusion Criteria:~* Symptomatic poorly controlled diabetes~* Recent cardiac or cerebrovascular event~* Serum creatinine \> = 2.0 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin plus open-label TZD (A) (Type: EXPERIMENTAL): Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)
- Saxagliptin plus open-label TZD (B) (Type: EXPERIMENTAL): Saxagliptin PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)
- Placebo plus open-label TZD (C) (Type: PLACEBO_COMPARATOR): Placebo PLUS pioglitazone OR rosiglitazone~PLUS open-label metformin (as needed as rescue medication)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Male and female patients with type 2 diabetes and with glomerular filtration rate (GFR) \<30 ml/min, who are not on chronic dialysis.~* Insufficient glycemic control (hemoglobin A1c (HbA1c) between 7.0% and 10.0%)~* Age 18 or over and not older than 80 years~Exclusion criteria:~* Treatment with any other anti diabetic drug other than insulin and/or sulphonylurea within 3 months prior to informed consent~* Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent~* Unstable or acute congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BI 1356 (Type: EXPERIMENTAL): patient to receive a tablet containing BI 1356 once daily
- placebo (Type: PLACEBO_COMPARATOR): patient to receive a tablet identical to BI 1356 once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sign Here: How to Conduct Informed Consent With Deaf Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18+~* self-identification as a healthcare provider, medical student, or nursing student~* current or recent engagement in informed consent for treatment~* access to an informed consent form that can be used for a simulated informed consent session~* We will also screen participants' self-reported level of experience with Deaf people, as we aim to recruit participants with little-to-no prior experience interacting with Deaf people to reflect the most probable real-word encounter that a Deaf person would have when receiving healthcare services.~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sign Here training intervention (Type: EXPERIMENTAL): Participants randomized to the experimental condition will view the new Sign Here training film for healthcare providers.
- Intervention as usual (Type: OTHER): Participants randomized to intervention as usual will review Communicating with People Who Are Deaf or Hard of Hearing in Hospital Settings (https://archive.ada.gov/hospcombrprt.pdf)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Nicotine Replacement for Alcoholic Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Males and females at least 18 years old.~* English speaking.~* Meets criteria for alcohol dependence or alcohol abuse.~* Must complete an alcohol detoxification program prior to entering the study.~* Currently smoking 15 or more cigarettes per day and have at least a 3 year history of smoking.~* Have a current desire to stop smoking and stop drinking.~* Willing to complete followup assessments up to 12 months after treatment.~* Willing to provide names of 2 people who can help locate the subject at followup and the name of one person who can verify information about alcohol and tobacco use.~* One person per household.~Exclusion Criteria:~* Allergy to nicotine patch or nicotine gum.~* Weigh less than 100 pounds.~* Use other nicotine products, such as cigars, pipes or smokeless tobacco.~* Severe skin disorder.~* Active peptic ulcer.~* Active joint disease.~* Heart attack within 3 months prior to entering the study.~* Pregnant or breastfeeding female who are not on birth control.~* Currently taking medication to treat alcoholism or smoking, such as naltrexone, disulfiram or bupropion.~* Poor vision or hearing that would interfere with using a cell phone.~* Lack of transportation to the treatment site or live at least one hour from the treatment site.~* Homeless.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nicotine patch plus placebo gum (Type: PLACEBO_COMPARATOR): Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Placebo gum was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. The placebo gum (manufactured by Fertin Pharma A/S, Vejle, Denmark) contained 2.6% cayenne pepper to simulate the taste of nicotine. Use of the gum was encouraged for 24 weeks.
- Nicotine patch plus active gum (Type: ACTIVE_COMPARATOR): Subjects in both arms were instructed to use one 21-mg (Nicoderm CQ®) nicotine patch daily for 8 weeks followed by one 14-mg patch daily for 2 weeks, then followed by one 7-mg patch daily for 2 weeks, for a total of 12 weeks of nicotine patch therapy. Nicotine gum (2 mg uncoated mint Nicorette®) was given for ad libitum use, with encouragement to use at least six pieces per day, up to a maximum of 20 pieces per day. Use of the gum was encouraged for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Fermentable Carbohydrate on Glucose Homeostasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Investigation 1 and 3: An oral glucose tolerance test diagnostic of impaired glucose tolerance as defined by the WHO as a fasting plasma glucose\<7.0mmol/l and a 2-h plasma glucose ≥7.8 and \<11.1mmol/l and/or impaired fasting glucose, defined by the American Diabetes Association as a fasting plasma glucose of \>5.6 and \<6.9mmol/L.~* Investigation 2: An oral glucose tolerance test diagnostic of impaired glucose tolerance as defined by the WHO as a fasting plasma glucose\<7.0mmol/l and a 2-h plasma glucose ≥7.8 and \<11.1mmol/l. For investigation 2, people with only IFG will be excluded.~* All investigations:~* Adults over 18 years of age~* Males and Females with a BMI between 25-35 kg/m2. The BMI range of between 25-35Kg/m2 has been chosen as this is the range that the majority of overweight people fall into (1). At this level of overweight and obesity there is an increase in the risk of type 2 diabetes. Above 40 kg/m2 there appears to be decreased success with lifestyle advice.~* The volunteers should have given full written consent.~* Have had a stable body weight for the last 6 months with no more than a 5% change in body weight over 6 months.~Exclusion Criteria:~* Adults less than 18 years of age.~* Volunteers with a major metabolic disease - including diabetes.~* A normal oral glucose tolerance test or that diagnostic of diabetes by the WHO criteria.~* Pregnant and lactating women.~* Males and Females with a BMI less than 25kg/m2 or greater than 35kg/m2~* Volunteers unable to give informed consent for themselves.~* Has lost or gained 5% of their normal body weight in the last 6 months.~* Has a known/diagnosed gastrointestinal problem such as inflammatory bowel disease, irritable bowel syndrome etc~* Failure of the medical examination for inclusion into the study~* Those with anaemia (Hb \<10g/l)~* Drug or alcohol abuse in the last 2 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inulin (Type: EXPERIMENTAL): Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.
- Cellulose (Type: PLACEBO_COMPARATOR): Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Electrocardiogram Clinical Validation Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals who are 22 years of age and older~* Able to read, understand, and provide written informed consent~* Willing and able to participate in the study procedures as described in the consent~* Have a wrist circumference that fits within the band~* Able to communicate effectively with and follow instructions from the study staff~* For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening~Exclusion Criteria:~* Physical disability that precludes safe and adequate testing~* Mental impairment resulting in limited ability to cooperate~* Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD)~* Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, increases the risk to the subject or renders data uninterpretable~* Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis within 90 days of screening~* Stroke or transient ischemic attack within 90 days of screening~* Subjects taking rhythm control drugs~* Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis on both wrists or over electrode attachment sites~* Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands primarily used in wrist worn fitness devices~* A history of abnormal life-threatening rhythms as determined by the investigator~* Significant tremor that prevents subject from being able to hold still~* Pregnant women: Women who are pregnant at the time of study participation~* For subjects enrolled into the sinus rhythm population, they must not have any diagnosis of AF

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Atrial fibrillation (AF) (Type: OTHER): Patient with a known history of AF who are in AF at the time of study screening.
- Normal Sinus Rhythm (SR) (Type: OTHER): Patient with no known diagnosis of AF or other arrhythmia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Key Inclusion Criteria:~* Males and females, 18 to 70 years of age~* Hepatitis C virus (HCV) genotype 1a or 1b~* HCV-treatment naive~* HCV RNA \>10,000 IU/mL at screening~* HIV-1 infection (approximately 250 patients receiving highly active antiretroviral therapy \[HAART\], up to 50 patients not receiving HAART)~* For patients receiving HAART, HIV RNA must be below \<40 copies/mL at screening and must be \<400 copies/ml for at least 6 months prior to screening~Key Exclusion Criteria:~* Patients receiving HAART who first initiated antiretroviral therapy within the last 6 months of Day 1~* Patients receiving HAART who have changed their antiretroviral regimen due to safety or efficacy associated to HIV treatment within the last 3 months prior to Day 1. However, if changes are required to a patient's HAART regimen to meet the requirements of the protocol, these changes are allowed at the screening visit. The patient should wait a minimum of 1 month prior to Day 1 after a repeat of HIV viral load has been confirmed, \<40 copies/ mL~* Use of prohibited HAART regimens within 1 month of Day 1 and throughout the treatment period of the trial (patients receiving HAART who have changed their antiretroviral regimen to initiate any HCV treatment within 6 weeks prior to Day 1)~* Laboratory values:~  1. Neutrophil count \<1500 cells/μL (\<1200 cells/ μL for Blacks)~ 2. Platelet count \<90,000 cells/μL~ 3. Hemoglobin ≤12 g/dL for females, hemoglobin ≤13 g/dL for males~ 4. Total bilirubin ≥34 μmol/L (or ≥2 mg/dL) unless a patient has a documented history of Gilbert's disease or antiretroviral regimen contains atazanavir~ 5. Alanine aminotransferase ≥5\*upper limit of normal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Daclatsvir + Ribavirin + PEG-Interferon alfa-2a (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have received 3 infusions in the HORIZON-Pivotal Fracture (PFT) Study.~Exclusion Criteria:~* Poor kidney, eye, or liver health~* Use of certain therapies for osteoporosis in the HORIZON-PFT study (other than the study medication)~* Abnormal calcium levels in the blood~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 68 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid 6 (Type: EXPERIMENTAL): Patients who received Zoledronic acid for 3 years in the core study (CZOL446H2301; NCT00049829) received a single intravenous infusion of 5 mg Zoledronic acid once a year for 3 years (at Months 36, 48 and 60) in this extension study for a total of 6 years of treatment.
- Zoledronic Acid 3 Placebo 3 (Type: PLACEBO_COMPARATOR): Patients who were treated with Zoledronic acid for 3 years in the core study received a single intravenous matching Placebo infusion once a year for 3 years in this extension study.
- Placebo 3 Zoledronic Acid 3 (Type: EXPERIMENTAL): Patients who were treated with placebo for 3 years in the core study received 5 mg Zoledronic acid in a single intravenous infusion once a year for 3 years (at Months 36, 48 and 60) in this extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria: Japanese adult, on statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks, fasting LDL-C greater than or equal to 115 mg/dL (3.0 mmol/L), fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L); Exclusion Criteria: New York Heart Association (NYHA) class III or IV, poorly controlled hypertension, recently diagnosed or poorly controlled type 2 diabetes, last known left ventricular ejection fraction \< 30%, myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), stroke, planned cardiac surgery or revascularization within 6 months of randomization, uncontrolled cardiac arrhythmia.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
- Placebo Q4W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
- Evolocumab 70 mg Q2W (Type: EXPERIMENTAL): Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 140 mg Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 280 mg Q4W (Type: EXPERIMENTAL): Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 420 mg Q4W (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Body and Social Behavior

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-35 years old~* Have a same-gender friend willing to participate in the second study session~Exclusion Criteria:~* Are not a student~* Have already received the annual influenza vaccine or had the flu this season~* Report current illness/sickness symptoms, including upper respiratory symptoms~* Report any major medical conditions (e.g., diabetes, asthma)~* Use mood or immune altering medications (e.g., anti-depressants)~* Current regular nicotine/tobacco use (i.e., daily use of cigarettes or e-cigarettes)~* Have an allergy to eggs~* Have had COVID-19 in past two weeks~* Current or history of depression or anxiety~* Have had Guillain-Barre Syndrome~* Are allergic to vaccine or ingredients present in vaccine~* Have had an adverse reaction to a blood draw, including to needles or sight or blood~* Weigh less than 110 pounds~* Are unwilling to be video/audio recorded during the social interaction tasks~* Are unwilling to be unmasked during the social interaction tasks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Influenza Vaccine (Type: EXPERIMENTAL): Experimental group given influenza vaccine (Flulaval)
- Sham Vaccine (Type: PLACEBO_COMPARATOR): The control group given a placebo (saline injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete